In sur­prise switch, Bris­tol-My­ers is sell­ing off block­buster Ote­zla, promis­ing to com­plete Cel­gene ac­qui­si­tion — just lat­er

Apart from re­veal­ing its check­point in­hibitor Op­di­vo blew a big liv­er can­cer study on Mon­day, Bris­tol-My­ers Squibb said its plans to swal­low Cel­gene will re­quire the sale of block­buster pso­ri­a­sis treat­ment Ote­zla to keep the Fed­er­al Trade Com­mis­sion (FTC) at bay.

The an­nounce­ment — which has po­ten­tial­ly de­layed the com­ple­tion of the takeover to ear­ly 2020 — irked in­vestors, trig­ger­ing the New York-based drug­mak­er’s shares to tum­ble Mon­day morn­ing in pre­mar­ket trad­ing.

Cel­gene’s Ote­zla, ap­proved in 2014 for pso­ri­a­sis and pso­ri­at­ic arthri­tis, is a ris­ing star. It gen­er­at­ed glob­al sales of $1.6 bil­lion last year, up from the near­ly $1.3 bil­lion in 2017. Apart from the par­tial over­lap of Bris­tol-My­ers in­jectable Oren­cia, the com­pa­ny’s ri­val oral TYK2 pso­ri­a­sis drug is in late-stage de­vel­op­ment, af­ter the firm post­ed en­cour­ag­ing mid-stage da­ta on the drug, BMS-986165, last fall. With Mon­day’s de­ci­sion, it ap­pears Bris­tol-My­ers is fa­vor­ing its ex­per­i­men­tal drug, and dis­count­ing Ote­zla’s fu­ture.

The move blind­sided some an­a­lysts. Cred­it Su­isse’s Vamil Di­van not­ed just days ago:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER